A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer: Supplementary appendix

Introduction: In the absence of head-to-head trials comparing immunotherapies for advanced

nonsquamous non-small-cell lung cancer (NsqNSCLC), a network meta-analysis (NMA) was conducted to

compare the relative efficacy of these treatments. Materials & methods: A systematic literature review of

randomized controlled trials evaluating first-line-to-progression and second-line treatments for advanced

NsqNSCLC informed Bayesian NMAs for overall survival (OS) and progression-free survival (PFS) end points.

Results: Among first-line-to-progression treatments, pembrolizumab + pemetrexed + platinum showed

the greatest OS benefit versus other regimens and a PFS benefit versus all but three regimens. Among

second-line treatments, an OS benefit was seen for atezolizumab, nivolumab and pembrolizumab versus

docetaxel. Conclusion: Pembrolizumab + pemetrexed + platinum showed the maximum OS benefit in

the first-line setting. In the second-line setting, anti-PD-1/anti-PD-L1 monotherapies were better than

docetaxel.